Dr. Shin'ichi Takeda is currently the honorary Director general, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP) in Tokyo. He was initially trained as a clinical Neurologist and then received a Ph.D. degree in Muscle Biology in 1981. He had a long term laboratory experience including at Pasteur Institute Paris (1987-1992), and focused his research on development of molecular therapy of Duchenne muscular dystrophy (DMD) after he came back to Japan and has gotten the position in NCNP in 1992. Besides his efforts to establish dystrophic dog colony (*Ann Neurol*, 2009) and to develop exon skipping drug for DMD (*Sci Transl Med*, 2018; *Ann Clin Transl Neurol,* 2020), he has been particularly interested in muscle stem cells and regenerative medicine. Indeed, he has been participated in characterization of muscle satellite cells (Stem Cells, 2007), which finally leads to the distinct work (*Nature*, 2018). He has been also engaged in the work for another progenitor in skeletal muscle, mesenchymal progenitors (*Nat Cell Biol*, 2010). He then focused on induction of myogenic precursor cells from human induced Pluripotent Stem (iPS) cells and the role of the cells in regenerative medicine in DMD (*Sci Rep*, 2018; *Commun Biol*, 2020). He was also working as an associate editor for review of J. Neuromuscular Diseases since 2013, and an associate editor of Am. J. Pathology since 2014, an Executive Board member of CINRG since 2019, and an Extended Committee member of TREAT-NMD TACT since 2020.